RE: RE: Another loan in the works? Endo pays the external costs of the trial and BNC covers manufacturing related costs. Or at least that is my understanding given the limited information available.
But with diminishing cash reserves I am taking a more broad view of a 1 to 2 year landscape. How do they plan another trial with 10 months cash on hand? How do they plan anything for that matter with a fully staffed manufacturing plant producing nothing but heat and hydro bills? At what point do they just give up on Econiche and take on contract manufacturing that actually produces cash flow?
We either need another loan that the Greeks would balk at, an even more attractive share+warrant dillution in the 25 cent range, an asset fire sale or they miraculously come up with some unforseen approval or marketing deal that would demonstrate rapid cash flow.
I don't see any artificial run up in the share price to indicate a PP, I can't imagine that they would enter into another historically bad loan arrangement, and McRae grossly overvalues his assets relative to reality... so maybe, just maybe, they have something refreshing in the works.
As someone pointed out today, there was a substantial portion of the January 2011 financing set aside for acquisitions! That is 100% correct...acquisitions...and that was just one year prior to the most recent Royalty Capital "lifeline".
I apologize if I offend anybody in questioning their financial prowess!